Frequency and Nature of Genomic Alterations in ERBB2-Altered Urothelial Bladder Cancer.

Jacob B LearyThomas EnrightDimitra Rafailia BakaloudiAlina BasnetGennady BratslavskyJoseph JacobPhilippe E SpiessRoger LiAndrea NecchiAshish M KamatDean C PavlickNatalie DanzigerRichard S P HuangDouglas I LinLiang ChengJeffrey RossRafee TalukderPetros D Grivas

Published in: Targeted oncology (2024)

We noted important differences in co-occurring GA in ERBB2-altered (ECDmut+, KDmut+, amp+) versus ERBB2wt UBC, as well as higher mean TMB and higher APOBEC mutational signature in the ERBB2-altered groups. Our results can help refine future clinical trial designs and elucidate possible response and resistance mechanisms for ERBB2-altered UBC.

Keyphrases

tyrosine kinase
clinical trial
randomized controlled trial
gene expression
high grade
protein kinase
dna methylation
phase ii